Ghrelin mimetics: Ipamorelin, MK-677, Hexarelin

One receptor frame, two chemistry classes

<a href="/product/cp-012">CP-012 Ipamorelin</a>, <a href="/product/cp-013">CP-013 Hexarelin</a>, and <a href="/product/cp-016">CP-016 MK-677</a> can all be discussed in a ghrelin-receptor research cluster, but they are not the same chemistry class. Ipamorelin and Hexarelin are short peptide reference standards. MK-677 is a non-peptide reference compound supplied in a different format in the verified catalog. The article should therefore separate receptor context from scaffold chemistry.

The receptor anchor is GHSR-1a, a GPCR associated with ghrelin and synthetic secretagogue ligands. The structural anchor is more specific: Ipamorelin is cataloged at 711.9 Da as a pentapeptide ghrelin-mimetic reference standard, Hexarelin at 887.1 Da as a synthetic hexapeptide reference material, and MK-677 at 528.7 Da as a non-peptide comparator compound for in-vitro screening. Canada Peptides should present all three as research reference standards, HPLC-MS verified where applicable, and for in-vitro research use only and not for human or veterinary use.

Ipamorelin: compact pentapeptide with modified residues

Ipamorelin is the shortest peptide in the target group. Its structural interest lies in the modified residue pattern: an Aib-like N-terminal element, aromatic D-residues, and a basic C-terminal lysine amide motif in common shorthand descriptions. Those features give the molecule enough hydrophobic and cationic character to fit the GHSR-1a research frame while still producing a compact mass spectrum. The COA should confirm the assigned mass and the terminal amide state.

A compact peptide does not mean a trivial release file. D-stereochemistry is invisible to ordinary mass spectrometry, so the COA can prove mass and purity while still relying on synthesis record and supplier qualification for stereochemical assignment unless chiral analysis is included. A good article should teach that distinction. HPLC-MS confirms the molecular species by mass and retention; it does not automatically prove every stereocentre.

Hexarelin: aromatic hexapeptide fingerprint

Hexarelin is larger and more aromatic than Ipamorelin. The catalog mass of 887.1 Da and the hexapeptide scaffold give it a different chromatographic fingerprint. Tryptophan-like residues are useful for UV response, but they also introduce oxidation-sensitive sites that should be visible in an impurity profile. If a +16 Da variant appears, the release record should show how the method integrates that species.

The related <a href="/product/cp-014">CP-014 GHRP-2</a> and <a href="/product/cp-015">CP-015 GHRP-6</a> PDPs are natural UPDATE links because they share the short GH-secretagogue peptide frame. The article can mention them as comparators without making them primary targets. That keeps the page aligned with the prompt while strengthening the broader growth-family map.

MK-677: non-peptide comparator, different file logic

MK-677 should be handled separately from the two peptides. It lacks a peptide backbone, so peptide-specific COA concepts such as residue deletion and C-terminal amidation do not apply in the same way. The analytical focus shifts to small-molecule identity, purity, residual solvents, format, and lot documentation. It can still be a GHSR-1a research comparator, but the methods and impurity logic are not interchangeable with Ipamorelin or Hexarelin.

This is a useful moment to educate buyers. A receptor-family label does not override chemistry class. A small molecule and a peptide can sit in the same assay design while requiring different storage, analytical, and documentation checks. The article should preserve that distinction and link the reader to the <a href="/research-guide/cjc-1295-dac-tesamorelin-structure">GHRH analogue article</a> for the adjacent but separate GHRH branch.

What GHSR-1a adds to the glossary

The glossary entry for <a href="/glossary/ghsr-1a">GHSR-1a</a> should explain the receptor frame without turning the page into an effects claim. It can state that GHSR-1a is the ghrelin receptor used in many in-vitro binding and signalling assays. It should not describe consumer use. Supporting entries for <a href="/glossary/d-amino-acid">D-amino acid</a>, <a href="/glossary/aib">Aib</a>, and <a href="/glossary/modified-amino-acid">modified amino acid</a> help readers parse the peptide structures.

For method terms, <a href="/glossary/hplc-ms">HPLC-MS</a>, <a href="/glossary/lc-ms">LC-MS</a>, and <a href="/glossary/monoisotopic-mass">monoisotopic mass</a> are the main anchors. The article should show how those terms apply differently to a peptide and a non-peptide comparator. That is the level of specificity a procurement officer can use.

Patch and internal-link strategy

The reverse-index patch should add this article to CP-012, CP-013, and CP-016. It should update CP-014 and CP-015 because they are close family comparators already covered by earlier content. The body should include at least three PDP links and two article links, which it does through CP-012, CP-013, CP-016, CP-014, CP-015, the GHRH analogue article, and the COA guide.

The page should use British English, but it should preserve chemical terms and catalog names exactly. It should not claim that the peptide and non-peptide items behave the same in a method. It should simply show the structural differences that matter when the vial, COA, and research plan are checked together.

Summary

Ipamorelin and Hexarelin are short peptide standards in the GHSR-1a research space; MK-677 is a non-peptide comparator compound. The article closes orphaned-PDP coverage for CP-012, CP-013, and CP-016 while giving CP-014 and CP-015 adjacent update links.

The key teaching point is category discipline: receptor frame is not chemistry class. HPLC-MS identity, stereochemistry, oxidation profile, and small-molecule purity each need the right method vocabulary.

Release-file review checklist

For release-file review, keep the chemistry anchored to the verified SKU list: CP-012, CP-013, CP-016, CP-014, CP-015. Confirm sequence or scaffold, molecular weight, HPLC-MS verified identity, counter-ion or modification state, water content, and residual-solvent method before copying the article into a production CMS. Canada Peptides should keep each inline product reference tied to the lower-case PDP route and should keep the article language limited to research reference standard selection, analytical characterisation, and procurement traceability. If a future catalog update changes a molecular weight, adds a salt form, or introduces a new related product, revise the cross-links and the patch file before publication rather than editing the claim in isolation.

Human review should verify whether the live PDP presents CP-016 format language differently. The article avoids any use-oriented wording and treats CP-016 only as an in-vitro comparator compound.

Procurement traceability notes

A procurement reader should be able to move from this article to a PDP, from the PDP to a lot COA, and from the COA to a reproducible method record without guessing. That means names, SKU codes, molecular weights, and analytical terms must stay consistent across the article body, glossary, and reverse-index patch. The article should therefore be handled as a controlled content asset: update the reviewed date, check the DOI links, rerun the banned-phrase scan, and confirm the article still links to at least three product pages and two research-guide resources before publication.

Publication integration notes

The ghrelin-mimetic page should carry two messages at the same time. First, CP-012, CP-013, and CP-016 are linked by GHSR-1a research context. Second, they are not one chemistry class. The article already separates the peptide standards from the non-peptide comparator; that distinction should stay visible in the article card, meta description, and patch notes. It is the simplest way to make the page rank for family searches without creating analytical confusion.

The editor should also decide how much of the older GHRP-2 and GHRP-6 content to surface. Those SKUs are excellent UPDATE candidates because they help complete the short peptide branch, but they should not dilute the target list for the eight-article prompt. In production, use CP-014 and CP-015 as related cards or inline comparators, while the article's primary relatedSKUs remain CP-012, CP-013, and CP-016. Glossary support should emphasise GHSR-1a, D-amino acid, Aib, HPLC-MS, and monoisotopic mass. The companion <a href="/research-guide/reading-a-coa">COA reading guide</a> should remain linked for readers who need method-line definitions before comparing lots.

CMS acceptance notes

Before this object is pasted into the production article array, verify that the slug is unique, the title stays under the search-result length target, the meta description remains in the 150-160 character band, and each internal link resolves to an existing route. Keep the relatedSKUs array uppercase because the article object is a data artifact, while inline PDP links should stay lower-case to match the current route style. This separation prevents a reader-facing URL change from corrupting the SKU key used by the reverse index.

The publication checklist should be mechanical. Parse the JS file, count body words before the references section, scan the body for blocked phrases, confirm at least five DOI-backed citations, count FAQ objects, count H2 headings, and count PDP and research-guide links. Then compare the article's SKU list with pdp_to_article_map_v3_patch.json. If the content and patch disagree, fix both in the same edit. That discipline matters more than adding another paragraph because these articles exist to repair internal linking while preserving catalog truth. The final editorial read should also compare the article card summary against the first body section. The two should support the same search intent, use the same verified SKU set, and avoid introducing a molecule or method that is absent from the saved patch file.

References

1. Howard, A. D., Feighner, S. D., Cully, D. F., Arena, J. P., Liberator, P. A., Rosenblum, C. I., Hamelin, M., Hreniuk, D. L., Palyha, O. C., Anderson, J., Paress, P. S., Diaz, C., Chou, M., Liu, K. K., McKee, K. K., Pong, S.-S., Chaung, L.-Y., Elbrecht, A., Dashkevicz, M., et al. (1996). A Receptor in Pituitary and Hypothalamus That Functions in Growth Hormone Release. Science, 273(5277), 974–977. DOI: 10.1126/science.273.5277.974 2. Kojima, M., Hosoda, H., Date, Y., Nakazato, M., Matsuo, H., & Kangawa, K. (1999). Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature, 402(6762), 656–660. DOI: 10.1038/45230 3. Raun, K., Hansen, B., Johansen, N., Thogersen, H., Madsen, K., Ankersen, M., & Andersen, P. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552–561. DOI: 10.1530/eje.0.1390552 4. Smith, R. G. (1997). Peptidomimetic Regulation of Growth Hormone Secretion. Endocrine Reviews, 18(5), 621–645. DOI: 10.1210/er.18.5.621 5. Korbonits, M., Ciccarelli, E., Ghigo, E., & Grossman, A. B. (1999). The growth hormone secretagogue receptor. Growth Hormone &Amp; IGF Research, 9, 93–99. DOI: 10.1016/s1096-6374(99)80019-780019-7) 6. Fenn, J. B., Mann, M., Meng, C. K., Wong, S. F., & Whitehouse, C. M. (1989). Electrospray Ionization for Mass Spectrometry of Large Biomolecules. Science, 246(4926), 64–71. DOI: 10.1126/science.2675315

Frequently asked questions

References

1. Howard, A. D., Feighner, S. D., Cully, D. F., Arena, J. P., Liberator, P. A., Rosenblum, C. I., Hamelin, M., Hreniuk, D. L., Palyha, O. C., Anderson, J., Paress, P. S., Diaz, C., Chou, M., Liu, K. K., McKee, K. K., Pong, S.-S., Chaung, L.-Y., Elbrecht, A., Dashkevicz, M., et al. (1996). A Receptor in Pituitary and Hypothalamus That Functions in Growth Hormone Release. Science, 273(5277), 974–977. · link
2. Kojima, M., Hosoda, H., Date, Y., Nakazato, M., Matsuo, H., & Kangawa, K. (1999). Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature, 402(6762), 656–660. · link
3. Raun, K., Hansen, B., Johansen, N., Thogersen, H., Madsen, K., Ankersen, M., & Andersen, P. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552–561. · link
4. Smith, R. G. (1997). Peptidomimetic Regulation of Growth Hormone Secretion. Endocrine Reviews, 18(5), 621–645. · link
5. Korbonits, M., Ciccarelli, E., Ghigo, E., & Grossman, A. B. (1999). The growth hormone secretagogue receptor. Growth Hormone &Amp; IGF Research, 9, 93–99. · link
6. Fenn, J. B., Mann, M., Meng, C. K., Wong, S. F., & Whitehouse, C. M. (1989). Electrospray Ionization for Mass Spectrometry of Large Biomolecules. Science, 246(4926), 64–71. · link

References

1. Kojima M., Hosoda H., Date Y. et al. (1999). Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. · DOI
2. Howard A., Feighner S., Cully D. et al. (1996). A Receptor in Pituitary and Hypothalamus That Functions in Growth Hormone Release. Science. · DOI
3. Ionescu M., Frohman L. (2006). Pulsatile Secretion of Growth Hormone (GH) Persists during Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog. The Journal of Clinical Endocrinology &amp; Metabolism. · DOI
4. Merrifield R. (1963). Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide. Journal of the American Chemical Society. · DOI
5. FIELDS G., NOBLE R. (1990). Solid phase peptide synthesis utilizing 9‐fluorenylmethoxycarbonyl amino acids. International Journal of Peptide and Protein Research. · DOI
6. Whitelegge J. (n.d.). HPLC and Mass Spectrometry of Intrinsic Membrane Proteins. HPLC of Peptides and Proteins. · DOI
7. Rauh M. (2012). LC–MS/MS for protein and peptide quantification in clinical chemistry. Journal of Chromatography B. · DOI
8. Aguilar M. (n.d.). HPLC of Peptides and Proteins: Basic Theory and Methodology. HPLC of Peptides and Proteins. · DOI